Bostic v. Georgia-Pacific Corp.
439 S.W.3d 332
Tex.2014Background
- Timothy Bostic (born 1962) developed mesothelioma in 2002 and died in 2003; his relatives sued Georgia‑Pacific and others alleging asbestos exposure from Georgia‑Pacific joint compound contributed to his disease.
- Trial jury apportioned 75% responsibility to Georgia‑Pacific and 25% to Knox Glass; judgment awarded compensatory and punitive damages; the court of appeals rendered a take‑nothing judgment for legal insufficiency of causation evidence.
- Plaintiffs’ theory relied heavily on expert testimony that “each and every” asbestos exposure above background contributes to mesothelioma (an “any‑exposure” theory); experts did not quantify an approximate dose traceable to Georgia‑Pacific.
- Evidence showed multiple sources of asbestos exposure for Bostic (childhood drywall work with his father, summers at Knox Glass, other remodeling and brake work); only sporadic, imprecisely documented use of Georgia‑Pacific product was proved.
- The Court considered prior Texas toxic‑tort precedents (Flores and Havner) and Restatement guidance, and examined whether plaintiffs must prove but‑for causation or a defendant‑specific substantial‑factor (dose) contribution.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standard for causation in mesothelioma cases | Flores standard inasbestosis cases should not bar recovery; mesothelioma can result from very small exposures, so proof of any exposure to defendant’s product suffices | Same substantial‑factor framework as Flores should apply; dose matters | Court: Flores’s substantial‑factor framework applies to mesothelioma; "any‑exposure" is insufficient |
| Role of “but‑for” causation | Plaintiffs: court of appeals erred in reading Flores to require strict but‑for proof that without defendant the decedent would not have gotten mesothelioma | Georgia‑Pacific: but‑for is traditional test and relevant | Court: but‑for concept overlaps with substantial‑factor but strict but‑for proof is not required in multiple‑exposure asbestos cases; substantial‑factor is the operative test |
| Quantitative proof / Havner application (use of epidemiology) | Plaintiffs: epidemiology may be less available for low/occasional exposures; direct expert opinion and evidence of significant exposure suffice | Georgia‑Pacific: where direct causation lacking, plaintiff must show reliable studies that defendant’s exposure more than doubled risk (Havner) and show comparability | Court: where direct proof absent, plaintiff must show scientifically reliable evidence (epidemiology or equivalent) that exposure to defendant’s product more than doubled the plaintiff’s risk; dose must be quantified (approx., not mathematically precise) |
| Sufficiency of evidence in this case | Plaintiffs: expert testimony that each exposure contributed and testimony that Bostic had significant exposures sufficed | Georgia‑Pacific: plaintiffs failed to quantify dose from Georgia‑Pacific and failed to meet Havner criteria; other sources (Knox Glass) likely dominated | Court: evidence legally insufficient — plaintiffs failed to quantify dose attributable to Georgia‑Pacific or present reliable epidemiological proof that its product more than doubled Bostic’s risk |
Key Cases Cited
- Borg‑Warner Corp. v. Flores, 232 S.W.3d 765 (Tex. 2007) (adopted substantial‑factor causation and required defendant‑specific dose evidence in asbestos cases)
- Merrell Dow Pharm., Inc. v. Havner, 953 S.W.2d 706 (Tex. 1997) (where direct causation lacking, reliable epidemiological studies showing more than doubling of risk can support specific causation)
- E.I. du Pont de Nemours & Co. v. Robinson, 923 S.W.2d 549 (Tex. 1995) (expert scientific testimony must be reliable and grounded in accepted methods to be admissible)
- Rutherford v. Owens‑Illinois, 16 Cal.4th 953 (Cal. 1997) (permitted proof that plaintiff’s exposure to defendant’s asbestos was a substantial factor contributing to aggregate dose and risk)